IP Library Granted Patent US 9,637,473
Granted Patent B2
US 9,637,473 · App. 14/777,459 · Granted May 2, 2017

Acrylamide derivatives as antimalarial agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,637,473
App. No.
14/777,459
Granted
May 2, 2017
Kind
B2
Abstract

The invention relates to novel acrylamide derivatives of the formula I wherein R 1 , R 2 , R 3 , X, and ring A are as defined in the description, and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as especially malaria.

Claims (329)

1. A compound of the formula I:

wherein

ring A is a phenylene or pyridin-diyl ring, wherein the group —X—R 3 is attached to ring A in meta- or para-position with respect to the point of attachment of ring A to the —CH 2 — group;

R 1 represents phenyl, or 5- or 6-membered heteroaryl; wherein said phenyl or heteroaryl independently is unsubstituted, or mono-, di-, or tri-substituted, wherein the substituents are independently selected from (C 1-5 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy, and (C 1-3 )alkyl-SO 2 —;

X represents —NR 4 — wherein R 4 represents hydrogen or (C 1-3 )alkyl; —O—; or —(CO)—; and

R 3 represents

piperidin-4-yl which is optionally substituted on the nitrogen with (C 1-4 )alkyl;

5- or 6-membered heteroaryl wherein said heteroaryl independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy;

8- to 10-membered heteroaryl wherein said heteroaryl independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy;

unsubstituted phenyl; or

4-hydroxy-3-(diethylamino-methyl)-phenyl;

or X represents a direct bond and

R 3 represents

4-[(C 1-4 )alkyl]-piperazin-1-yl or pyrrolidine-1-yl; or

5- or 6-membered heteroaryl, wherein said heteroaryl independently is unsubstituted, or mono-substituted with (C 1-4 )alkyl;

or X represents —O— and R 3 represents —(C 2-4 )alkylene-NR 10 R 11 , wherein R 10 and R 11 independently represent (C 1-3 )alkyl; and

R 2 represents

—(C 2-4 )alkylene-NR 12 R 13 , wherein R 12 and R 13 independently represent (C 1-3 )alkyl, or R 12 and R 13 together with the nitrogen atom to which they are attached to form a morpholine ring; or

(C 3-7 )cycloalkyl which is mono-substituted with NR 14 R 15 , wherein R 14 and R 15 independently represent (C 1-3 )alkyl, or R 14 and R 15 together with the nitrogen atom to which they are attached to form a pyrrolidine ring; or

—(C 0-2 )alkylene-heterocyclyl, wherein said heterocyclyl is a 4- to 7-membered saturated monocyclic or 7- to 11-membered saturated bicyclic carbocyclic ring containing one ring nitrogen atom; wherein said heterocyclyl may carry one optional substituent attached to a ring carbon atom wherein said substituent is selected from hydroxy and fluoro; and wherein said heterocyclyl is unsubstituted or substituted on said ring nitrogen atom with a substituent selected from:

(C 1-6 )alkyl,

(C 2-3 )fluoroalkyl;

—(C 2-4 )alkylene-(C 1-4 )alkoxy;

—(C 2-4 )alkylene-NR 16 R 17 , wherein R 16 and R 17 independently represent (C 1-3 )alkyl;

(C 3-7 )cycloalkyl;

—(C 1-3 )alkylene-(C 3-7 )cycloalkyl;

bicyclo [2.2.1]hept-5-en-2-ylmethyl;

piperidin-4-yl, wherein said piperidin group is substituted at the nitrogen atom with (C 1-4 )alkyl;

2,2-diphenylethyl;

3-diethylaminomethyl-4-hydroxy-benzyl;

—(C 1-3 )alkylene-phenyl wherein the phenyl group is optionally mono- or di-substituted wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy; and

—(C 1-3 )alkylene-heteroaryl, wherein the heteroaryl is a 5- to 10-membered heteroaryl, which is optionally mono- or di-substituted wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy, phenyl, and —(CO)—(C 1-4 )alkyl;

with the exception of:

N-[3-(4-morpholinyl)-propyl]-N-[(3-phenoxyphenyl)-methyl]-3-phenyl-2-propenamide; and

N-[2-(4-morpholinyl)-ethyl]-N-[(3-phenoxyphenyl)-methyl]-3-phenyl-2-propenamide;

or a pharmaceutically acceptable salt of such a compound.

2. A compound according to claim 1 , which is also a compound of formula II

wherein

ring A is 1,4-phenylene, or pyridin-2,5-diyl;

R represents (C 1-5 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy, or (C 1-3 )alkyl-SO 2 —;

X represents —NR 4 — wherein R 4 represents hydrogen or methyl; or —O—; and

R 3 represents

piperidin-4-yl which is optionally substituted on the nitrogen with (C 1-4 )alkyl;

5- or 6-membered heteroaryl wherein said heteroaryl independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, and halogen;

10-membered heteroaryl wherein said heteroaryl independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and (C 1-3 )fluoroalkyl;

unsubstituted phenyl; or

4-hydroxy-3-(diethylamino-methyl)-phenyl;

or X represents a direct bond and

R 3 represents

4-[(C 1-4 )alkyl]-piperazin-1-yl or pyrrolidine-1-yl; or

5- or 6-membered heteroaryl, wherein said heteroaryl independently is unsubstituted, or mono-substituted with (C 1-4 )alkyl;

or X represents —O— and R 3 represents —(C 2-4 )alkylene-NR 10 R 11 , wherein R 10 and R 11 independently represent (C 1-3 )alkyl; and

R 2 represents

—(C 2-4 )alkylene-NR 12 R 13 , wherein R 12 and R 13 independently represent (C 1-3 )alkyl, or R 12 and R 13 together with the nitrogen atom to which they are attached to form a morpholine ring; or

(C 3-7 )cycloalkyl which is mono-substituted with NR 14 R 15 , wherein R 14 and R 15 independently represent (C 1-3 )alkyl, or R 14 and R 15 together with the nitrogen atom to which they are attached to form a pyrrolidine ring; or

heterocyclyl, wherein said heterocyclyl is a 4- to 7-membered saturated monocyclic or 7- to 11-membered saturated bicyclic carbocyclic ring containing one ring nitrogen atom; wherein said heterocyclyl may carry one optional fluoro substituent attached to a ring carbon atom; and wherein said heterocyclyl is substituted on said ring nitrogen atom with a substituent selected from:

(C 1-6 )alkyl,

(C 2-3 )fluoroalkyl;

—(C 2-4 )alkylene-(C 1-4 )alkoxy;

—(C 2-4 )alkylene-NR 16 R 17 , wherein R 16 and R 17 independently represent (C 1-3 )alkyl;

(C 3-7 )cycloalkyl;

—(C 1-3 )alkylene-(C 3-7 )cycloalkyl;

bicyclo[2.2.1]hept-5-en-2-ylmethyl;

piperidin-4-yl, wherein said piperidin group is substituted at the nitrogen atom with (C 1-4 )alkyl;

2,2-diphenylethyl;

3-diethylaminomethyl-4-hydroxy-benzyl;

—(C 1-3 )alkylene-phenyl wherein the phenyl group is optionally mono- or di-substituted wherein the substituents are independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, and (C 1-3 )fluoroalkyl; and

—(C 1-3 )alkylene-heteroaryl, wherein the heteroaryl is a 5- to 10-membered heteroaryl; wherein said heteroaryl is independently unsubstituted, or mono- or di-substituted wherein the substituents are independently selected from (C 1-4 )alkyl, phenyl, and —(CO)—(C 1-4 )alkyl;

or a pharmaceutically acceptable salt of such a compound.

3. A compound according to claim 1 wherein R 1 represents 4-trifluoromethylphenyl, or a pharmaceutically acceptable salt of such a compound.

4. A compound according to claim 1 , wherein

X represents —NR 4 — wherein R 4 represents hydrogen or methyl; and

R 3 represents

piperidin-4-yl which is optionally substituted on the nitrogen with (C 1-3 )alkyl;

6-membered heteroaryl selected from pyridinyl and pyrimidinyl, wherein said heteroaryl independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from methyl, methoxy, and fluoro;

quinolinyl which is mono-, or di-substituted wherein the substituents are independently selected from methyl, methoxy, chloro, and trifluoromethyl; or

4-hydroxy-3-(diethylamino-methyl)-phenyl;

or X represents a direct bond and

R 3 represents

4-[(C 1-4 )alkyl]-piperazin-1-yl or pyrrolidine-1-yl; or

5- or 6-membered heteroaryl selected from pyridinyl, pyrimidinyl, pyrazolyl, and thiazolyl, wherein said heteroaryl independently is unsubstituted, or mono-substituted with methyl;

or X represents —O— and R 3 represents dimethylaminopropyl;

or a pharmaceutically acceptable salt of such a compound.

5. A compound according to claim 1 , wherein

X represents —NR 4 — wherein R 4 represents hydrogen or methyl; and

R 3 represents

piperidin-4-yl which is optionally substituted on the nitrogen with (C 1-3 )alkyl; or

6-membered heteroaryl selected from pyridinyl and pyrimidinyl, wherein said heteroaryl independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from methyl, methoxy, and fluoro;

or a pharmaceutically acceptable salt of such a compound.

6. A compound according to claim 1 , wherein R 2 represents heterocyclyl selected from azetidinyl, pyrrolidinyl, piperidinyl, azepanyl, 2-aza-spiro[3.3]hept-6-yl, octahydro-cyclopenta[c]pyrrol-5-yl, and 3-aza-spiro[5.5]undec-9-yl; wherein in case said herocyclyl is piperidinyl, said heterocyclyl may carry one optional fluoro substituent attached to a ring carbon atom; wherein said heterocyclyl is substituted on the ring nitrogen atom with a substituent selected from:

methyl, ethyl, iso-propyl, n-propyl, 3-methylbutyl;

3,3,3-trifluoropropyl;

2-methoxy-1-methyl-ethyl;

2-dimethylamino-ethyl;

cyclopropyl, cyclopentyl;

cyclopropyl-methyl;

bicyclo[2.2.1]hept-5-en-2-ylmethyl;

1-methyl-piperidin-4-yl;

—(C 1-3 )alkylene-phenyl wherein the phenyl group is optionally mono- or di-substituted wherein the substituents are independently selected from methyl, methoxy, halogen, cyano, and trifluoromethyl; and

—(CH 2 )-heteroaryl, wherein the heteroaryl is a 5- to 10-membered heteroaryl selected from thiazolyl, isoxazolyl, oxazolyl, pyrazolyl, imidazolyl, pyridinyl, pyrimidinyl, imidazopyridinyl, benzimidazolyl, and indolyl; wherein said heteroaryl is independently unsubstituted or mono- or di-substituted with methyl;

or a pharmaceutically acceptable salt of such a compound.

7. A compound according to claim 1 , wherein R 2 represents heterocyclyl selected from piperidin-3-yl, piperidin-4-yl, 3-fluoro-piperidin-4-yl, 2-aza-spiro[3.3]hept-6-yl, and 3-aza-spiro[5.5]undec-9-yl; wherein said heterocyclyl is independently substituted on the ring nitrogen atom with with cyclopentyl or 1-methyl-piperidin-4-yl;

or a pharmaceutically acceptable salt of such a compound.

8. A compound according to claim 1 which is selected from the group consisting of:

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-piperidin-4-yl-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N—(S)-piperidin-3-yl-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-[1-(4-trifluoromethyl-benzyl)-piperidin-4-yl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(2-Methyl-oxazol-4-ylmethyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Ethyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3-Methyl-butyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopropylmethyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Bicyclo[2.2.1]hept-5-en-2-ylmethyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3,4-Dichloro-benzyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(4-Methyl-benzyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(4-Methoxy-benzyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-(1-phenethyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(2,2-Diphenyl-ethyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-N-[1-(3,3,3-trifluoro-propyl)-piperidin-4-yl]-acrylamide;

(E)-N-[1-(2-Methyl-2H-pyrazol-3-ylmethyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-[1-(1-phenyl-1H-pyrazol-4-ylmethyl)-piperidin-4-yl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3-Methyl-3H-imidazol-4-ylmethyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Imidazo[1,5-a]pyridin-3-ylmethyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(1-Methyl-1H-benzoimidazol-2-ylmethyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-(1-pyridin-2-ylmethyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-(1-pyridin-3-ylmethyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-[1-(2-methyl-pyrimidin-5-ylmethyl)-piperidin-4-yl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Imidazo[1,2-a]pyridin-7-ylmethyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(4-Cyano-benzyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(1-Acetyl-1H-indol-3-ylmethyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-(1-pyrimidin-2-ylmethyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-[1-(1-phenyl-ethyl)-piperidin-4-yl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopropylmethyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(2,5-Dimethyl-oxazol-4-ylmethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-(1-propyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(5-Methyl-isoxazol-3-ylmethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-[1-(4-methyl-thiazol-5-ylmethyl)-piperidin-4-yl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(2-Methyl-oxazol-4-ylmethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Imidazo[1,2-a]pyridin-3-ylmethyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-N-[1-(3,3,3-trifluoro-propyl)-piperidin-4-yl]-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-(1-thiazol-2-ylmethyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(1-Methyl-1H-imidazol-2-ylmethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-[1-(4-methyl-thiazol-2-ylmethyl)-piperidin-4-yl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(2,5-Dimethyl-2H-pyrazol-3-ylmethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3,5-Dimethyl-isoxazol-4-ylmethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Imidazo[1,5-a]pyridin-1-ylmethyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Imidazo[1,5-a]pyridin-3-ylmethyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-(1-pyrimidin-2-ylmethyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-(1-pyridin-3-ylmethyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-(1-pyrimidin-5-ylmethyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(1-Methyl-1H-pyrazol-4-ylmethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-[1-(2-methyl-pyrimidin-5-ylmethyl)-piperidin-4-yl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(2,3-Dimethyl-3H-imidazol-4-ylmethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3-Dimethylaminomethyl-4-hydroxy-benzyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3-Diethylaminomethyl-4-hydroxy-benzyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—((S)-1′-Methyl-[1,4′]bipiperidinyl-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—((R)-1′-Methyl-[1,4′]bipiperidinyl-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(1-Methyl-piperidin-4-yl)-azepan-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—((S)-1-Cyclopentyl-piperidin-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—((R)-1-Cyclopentyl-piperidin-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-azepan-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—[(S)-1-(3-Methyl-butyl)-piperidin-3-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—[(R)-1-(3-Methyl-butyl)-piperidin-3-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3-Methyl-butyl)-azepan-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[(3aR,6aS)-2-(1-Methyl-piperidin-4-yl)-octahydro-cyclopenta[c]pyrrol-5-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[3-(1-Methyl-piperidin-4-yl)-3-aza-spiro[5.5]undec-9-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-((3aR,6aS)-2-Cyclopentyl-octahydro-cyclopenta[c]pyrrol-5-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(3-Cyclopentyl-3-aza-spiro[5.5]undec-9-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[(3aR,6aS)-2-(3-Methyl-butyl)-octahydro-cyclopenta[c]pyrrol-5-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[3-(3-Methyl-butyl)-3-aza-spiro[5.5]undec-9-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(1-Methyl-piperidin-4-yl)-azepan-3-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-azepan-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3-Methyl-butyl)-azepan-3-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[2-(1-Methyl-piperidin-4-yl)-2-aza-spiro[3.3]hept-6-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(2-Cyclopentyl-2-aza-spiro[3.3]hept-6-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[2-(3-Methyl-butyl)-2-aza-spiro[3.3]hept-6-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-((3R,4S)-1-Cyclopentyl-3-fluoro-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[(3R,4S)-3-Fluoro-1-(3-methyl-butyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-((3R,4S)-3-Fluoro-1′-methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-((3S,4S)-3-Fluoro-1′-methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-((3S,4S)-1-Cyclopentyl-3-fluoro-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[(3S,4S)-3-Fluoro-1-(3-methyl-butyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—((S)-1-Ethyl-piperidin-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—((S)-1-Isopropyl-piperidin-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(2-Methoxy-1-methyl-ethyl)-piperidin-4-yl]-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(2-methyl-quinolin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(2,6-dimethyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(6-methoxy-quinolin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2,8-Bis-trifluoromethyl-quinolin-4-ylamino)-benzyl]-N-(1-cyclopentyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-N-[4-(7-trifluoromethyl-quinolin-4-ylamino)-benzyl]-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(pyrimidin-5-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(pyrimidin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-(4-phenylamino-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(2-methoxy-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(methyl-pyridin-3-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(7-Chloro-quinolin-4-ylamino)-benzyl]-N-(1-cyclopentyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(5-methyl-pyridin-2-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-pyrrolidin-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(6-methoxy-2-methyl-quinolin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-pyrrolidin-3-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-azetidin-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[6-(pyridin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[6-(methyl-pyridin-4-yl-amino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[6-(1-methyl-piperidin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-{6-[methyl-(1-methyl-piperidin-4-yl)-amino]-pyridin-3-ylmethyl}-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[6-(pyrimidin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[6-(2-methyl-pyrimidin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[6-(6-methyl-pyrimidin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[6-(pyridin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[6-(2-methyl-pyridin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[6-(methyl-pyridin-4-yl-amino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—((R)-1-Cyclopentyl-pyrrolidin-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N—((S)-1-Cyclopentyl-pyrrolidin-3-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-3-(4-Chloro-phenyl)-N-(1′-methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethoxy-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethoxy-phenyl)-acrylamide;

(E)-N—((S)-1-Isopropyl-piperidin-3-yl)-N-[6-(2-methyl-pyridin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-{3-[methyl-(2-methyl-pyridin-4-yl)-amino]-benzyl}-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[3-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[3-(3-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[3-(3-Fluoro-pyridin-4-ylamino)-benzyl]-N-(1-isopropyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[3-(pyrimidin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[3-(pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[6-(methyl-pyridin-4-yl-amino)-pyridin-2-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-{6-[methyl-(2-methyl-pyridin-4-yl)-amino]-pyridin-2-ylmethyl}-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[6-(2-methyl-pyridin-4-ylamino)-pyridin-2-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[6-(3-methyl-pyridin-4-ylamino)-pyridin-2-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[6-(3-Fluoro-pyridin-4-ylamino)-pyridin-2-ylmethyl]-N-(1-isopropyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[6-(pyridin-4-ylamino)-pyridin-2-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[5-(methyl-pyridin-4-yl-amino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[5-(methyl-pyridin-3-yl-amino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-{5-[methyl-(2-methyl-pyridin-4-yl)-amino]-pyridin-3-ylmethyl}-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[5-(2-methyl-pyridin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[5-(3-methyl-pyridin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[5-(3-Fluoro-pyridin-4-ylamino)-pyridin-3-ylmethyl]-N-(1-isopropyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[5-(pyrimidin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[5-(methyl-pyridin-2-yl-amino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[5-(pyridin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[3-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(4-isopropoxy-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(4-tert-butyl-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(4-difluoromethoxy-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethoxy-phenyl)-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(4-ethyl-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-propoxy-phenyl)-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(4-methoxy-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(3-methoxy-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(2-methoxy-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(4-chloro-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(3-chloro-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(2-chloro-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(4-fluoro-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(3-fluoro-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(2-fluoro-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-p-tolyl-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-m-tolyl-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-o-tolyl-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(6-trifluoromethyl-pyridin-3-yl)-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(4-methanesulfonyl-phenyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(2,4-dimethyl-thiazol-5-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-3-(1,5-dimethyl-1H-pyrazol-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(1,3,5-trimethyl-1H-pyrazol-4-yl)-acrylamide;

(E)-N-(3-Dimethylamino-propyl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-3-(4-Chloro-phenyl)-N-(3-dimethylamino-propyl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[6-(2-methyl-pyridin-4-ylamino)-pyridin-3-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-3-(4-Chloro-phenyl)-N-(1-cyclopentyl-piperidin-4-yl)-N-[6-(2-methyl-pyridin-4-ylamino)-pyridin-3-ylmethyl]-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[5-(2-methyl-pyridin-4-ylamino)-pyridin-2-ylmethyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-3-(4-Chloro-phenyl)-N-(1-cyclopentyl-piperidin-4-yl)-N-[5-(2-methyl-pyridin-4-ylamino)-pyridin-2-ylmethyl]-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-ylmethyl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(2-Methyl-pyridin-4-ylamino)-benzyl]-N-(3-morpholin-4-yl-propyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Methyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(4-Hydroxy-1-methyl-piperidin-4-ylmethyl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(2-Dimethylamino-ethyl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-{4-[methyl-(1-methyl-piperidin-4-yl)-amino]-benzyl}-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Benzyl-piperidin-4-yl)-N-{4-[methyl-(1-methyl-piperidin-4-yl)-amino]-benzyl}-3-(4-trifluoromethoxy-phenyl)-acrylamide;

(E)-3-(4-Cyano-phenyl)-N-(1′-methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-3-(4-Chloro-phenyl)-N-(1′-methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-3-(4-Difluoromethoxy-phenyl)-N-(1′-methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-phenyl-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(6-trifluoromethyl-pyridin-3-yl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-{4-[methyl-(2-methyl-pyridin-4-yl)-amino]-benzyl}-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(3-Diethylaminomethyl-4-hydroxy-phenylamino)-benzyl]-N-(1-methyl-piperidin-4-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Isopropyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-ylmethyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-ylmethyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(3-Methyl-butyl)-piperidin-4-ylmethyl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(4-Dimethylamino-cyclohexyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(4-Dimethylamino-cyclohexyl)-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-(4-pyrrolidin-1-yl-cyclohexyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[4-(Methyl-pyridin-4-yl-amino)-benzyl]-N-(4-pyrrolidin-1-yl-cyclohexyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1′-Methyl-[1,4′]bipiperidinyl-4-yl)-N-[4-(pyridine-4-carbonyl)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-[1-(2-Dimethylamino-ethyl)-piperidin-4-yl]-N-[4-(methyl-pyridin-4-yl-amino)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-yl)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-(4-pyridin-3-yl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-(4-pyridin-2-yl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(4-isopropyl-piperazin-1-yl)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(4-methyl-piperazin-1-yl)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(2-methyl-thiazol-5-yl)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(1-methyl-1H-pyrazol-3-yl)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-(4-pyrimidin-2-yl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-(4-pyrimidin-5-yl-benzyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(3-dimethylamino-propoxy)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-(2-pyrrolidin-1-yl-pyridin-4-ylmethyl)-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(pyridin-4-yloxy)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-N-(1-Cyclopentyl-piperidin-4-yl)-N-[4-(2,6-dimethyl-pyridin-4-yloxy)-benzyl]-3-(4-trifluoromethyl-phenyl)-acrylamide;

(E)-3-(4-Chloro-phenyl)-N-(2-dimethylamino-1-methyl-ethyl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-acrylamide; and

(E)-3-(4-Chloro-phenyl)-N-(1-cyclopropyl-piperidin-4-yl)-N-[4-(2-methyl-pyridin-4-ylamino)-benzyl]-acrylamide;

or a pharmaceutically acceptable salt of such a compound.

9. A pharmaceutical composition comprising a compound according to claim 1 , in free or pharmaceutically acceptable salt form, and a pharmaceutically acceptable carrier material.

10. A method for the treatment of malaria, said method comprising administering to a subject a pharmaceutically active amount of a compound according to claim 1 , in free or pharmaceutically acceptable salt form.

11. A compound according to claim 3 , wherein

X represents —NR 4 — wherein R 4 represents hydrogen or methyl; and

R 3 represents

piperidin-4-yl which is optionally substituted on the nitrogen with (C 1-3 )alkyl; or

6-membered heteroaryl selected from pyridinyl and pyrimidinyl, wherein said heteroaryl independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from methyl, methoxy, and fluoro;

or a pharmaceutically acceptable salt of such a compound.

12. A compound according to claim 3 , wherein R 2 represents heterocyclyl selected from piperidin-3-yl, piperidin-4-yl, 3-fluoro-piperidin-4-yl, 2-aza-spiro[3.3]hept-6-yl, and 3-aza-spiro[5.5]undec-9-yl; wherein said heterocyclyl is independently substituted on the ring nitrogen atom with with cyclopentyl or 1-methyl-piperidin-4-yl;

or a pharmaceutically acceptable salt of such a compound.

13. A compound according to claim 5 , wherein R 2 represents heterocyclyl selected from piperidin-3-yl, piperidin-4-yl, 3-fluoro-piperidin-4-yl, 2-aza-spiro[3.3]hept-6-yl, and 3-aza-spiro[5.5]undec-9-yl; wherein said heterocyclyl is independently substituted on the ring nitrogen atom with with cyclopentyl or 1-methyl-piperidin-4-yl;

or a pharmaceutically acceptable salt of such a compound.

14. A compound according to claim 11 , wherein R 2 represents heterocyclyl selected from piperidin-3-yl, piperidin-4-yl, 3-fluoro-piperidin-4-yl, 2-aza-spiro[3.3]hept-6-yl, and 3-aza-spiro[5.5]undec-9-yl; wherein said heterocyclyl is independently substituted on the ring nitrogen atom with with cyclopentyl or 1-methyl-piperidin-4-yl;

or a pharmaceutically acceptable salt of such a compound.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042464 FRAME: 0407. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 043017/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 042464/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2016
From: AISSAOUI, HAMED; BOSS, CHRISTOPH; CIANA, CLAIRE-LISE; KIMMERLIN, THIERRY; SIEGRIST, ROMAIN
To: ACTELION PHARMACEUTICALS LTD.
Reel/Frame 037672/0363 →